Menogaril in the treatment of malignant mesothelioma: A phase II study

C. A. Hudis; D. P. Kelsen

doi:10.1007/bf00873126

journal article Jun 01, 1992

Menogaril in the treatment of malignant mesothelioma: A phase II study

C. A. Hudis D. P. Kelsen

Investigational New Drugs Vol. 10 No. 2 pp. 103-106 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf00873126

Topics

No keywords indexed for this article. Browse by subject →

References

19

[1]

McCormack PM, Nagasaki F,et al.: Surgical treatment of pleural mesothelioma. J Thoracic Cardiovasc Surg 84:834, 1982 10.1016/s0022-5223(19)38932-9

[2]

Antman K: Malignant mesothelioma. NEJM 303:200, 1980 10.1056/nejm198007243030407

[3]

Antman K, Blum R,et al.: Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68:356, 1980 10.1016/0002-9343(80)90103-5

[4]

Brenner J, Sordillo PD,et al.: Malignant mesothelioma of the pleura: review of 123 patients. Cancer 49:2431, 1982 10.1002/1097-0142(19820601)49:11<2431::aid-cncr2820491134>3.0.co;2-w

[5]

Chainian AP, Pajak TF,et al.: Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Int Med 96 (part I):746, 1982 10.7326/0003-4819-96-6-746

[6]

Aisner J, Wiernik PH: Chemotherapy in the treatment of malignant mesothelioma. Sem Onc 8:335, 1981

[7]

Lerner H, Schoenfeld D,et al.: Malignant mesothelioma: the Eastern Cooperative Oncology Group experience. Cancer 52:1981, 1983 10.1002/1097-0142(19831201)52:11<1981::aid-cncr2820521102>3.0.co;2-p

[8]

Legha S, Muggia F: Therapeutic approaches to malignant mesothelioma. Ca Treat Rev 4:13, 1977 10.1016/s0305-7372(77)80016-9

[9]

Mossman BT, Gee JBL: Asbestos-related diseases. NEJM 320:1721, 1989 10.1056/nejm198906293202604

[10]

Mintzer DM, Kelsen DP,et al.: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Ca Treat Reports 69:711, 1985

[11]

Kelsen DP, Gralla R,et al.: Vindesine in the treatment of malignant mesothelioma: a phase II study. Ca Treat Reports 67:821, 1983

[12]

Bajorin D, Kelsen DP, Mintzer D: Phase II trial of mitomycin in malignant mesothelioma. Ca Treat Reports 71:857, 1987

[13]

Bhuyan BK, McGovern JP, Crampton SL: Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival. Ca Res 41:882, 1981

[14]

Egorin MG, Clawson RE,et al.: Cellular pharmacology of 7(R)-methylnogarol: a new anticancer agent. J Pharm Exp Ther 21:229, 1979

[15]

Bhuyan BK, Blowers CL, Shgars DK: Lethality of nogalomycin, nogalomycin analogs, and adriamycin to cells in different cell cycle phases. Ca Res 40:3437, 1980

[16]

Dodion P, Sessa C,et al.: Phase I study of intravenous menogaril administered intermittently. J Clin Onc 4:767, 1986 10.1200/jco.1986.4.5.767

[17]

McGovren JP, Neil GL,et al.: Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new antracycline antitumor agent. Cancer Res 38:4849, 1979

[18]

Lassus M: Personal communication

[19]

Investigational Drug Branch, NCI, Div of Cancer Treatment, CTEP Letter, 3∶1, August 24, 1984

Metrics

15

Citations

19

References

Details

Published: Jun 01, 1992
Vol/Issue: 10(2)
Pages: 103-106
License: View

Authors

Cite This Article

C. A. Hudis, D. P. Kelsen (1992). Menogaril in the treatment of malignant mesothelioma: A phase II study. Investigational New Drugs, 10(2), 103-106. https://doi.org/10.1007/bf00873126

Menogaril in the treatment of malignant mesothelioma: A phase II study

You May Also Like